Back to top
more

Bellerophon Therapeutics (BLPH)

(Delayed Data from OTC)

$0.06 USD

0.06
276

+0.02 (44.74%)

Updated Nov 21, 2024 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $0.69, marking a -1.78% move from the previous day.

Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know

Bellerophon Therapeutics (BLPH) closed the most recent trading day at $0.68, moving -1.93% from the previous trading session.

Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails

Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Bellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $7.65, marking a +1.06% move from the previous day.

Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?

Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.

Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know

Bellerophon Therapeutics (BLPH) closed at $10.04 in the latest trading session, marking a -0.4% move from the prior day.

Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know

Bellerophon Therapeutics (BLPH) closed the most recent trading day at $9.92, moving -0.6% from the previous trading session.

Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know

Bellerophon Therapeutics (BLPH) closed the most recent trading day at $10.98, moving -1.08% from the previous trading session.

Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus

Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid March Rally

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.

Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why

Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going

Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size

Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.

Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Walgreens (WBA) to Report Q3 Earnings: What's in Store?

Faster adoption of digital health and improved business environment are expected to have contributed to Walgreens' (WBA) third-quarter performance.

Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status

VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel

Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data

Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.

Reata (RETA) Soars on Potential Omaveloxolone NDA Filing

The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.

Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update

Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates

Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Company News for May 12, 2020

Companies In The News Are:

Company News for Mar 23, 2020

Companies In The News Are: BLPH, GNMK, WORK, SRNE